DE69231576D1 - Verwendung von Peptiden ZUR BEHANDLUNG VON KOMPLIKATIONEN UND PATHOLOGY BEI DIABETES - Google Patents

Verwendung von Peptiden ZUR BEHANDLUNG VON KOMPLIKATIONEN UND PATHOLOGY BEI DIABETES

Info

Publication number
DE69231576D1
DE69231576D1 DE69231576T DE69231576T DE69231576D1 DE 69231576 D1 DE69231576 D1 DE 69231576D1 DE 69231576 T DE69231576 T DE 69231576T DE 69231576 T DE69231576 T DE 69231576T DE 69231576 D1 DE69231576 D1 DE 69231576D1
Authority
DE
Germany
Prior art keywords
pathology
diabetes
peptides
treat complications
complications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69231576T
Other languages
English (en)
Other versions
DE69231576T2 (de
Inventor
Juergen Michaelis
Roger Hipkiss
Sianna Panagiotopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals Australia Pty Ltd
Kings College London
Original Assignee
Peptech Ltd
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptech Ltd, Kings College London filed Critical Peptech Ltd
Publication of DE69231576D1 publication Critical patent/DE69231576D1/de
Application granted granted Critical
Publication of DE69231576T2 publication Critical patent/DE69231576T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69231576T 1991-09-09 1992-09-09 Verwendung von Peptiden ZUR BEHANDLUNG VON KOMPLIKATIONEN UND PATHOLOGY BEI DIABETES Expired - Lifetime DE69231576T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPK827991 1991-09-09
PCT/AU1992/000480 WO1993004690A1 (en) 1991-09-09 1992-09-09 Method for the treatment of the complications and pathology of diabetes

Publications (2)

Publication Number Publication Date
DE69231576D1 true DE69231576D1 (de) 2000-12-28
DE69231576T2 DE69231576T2 (de) 2001-06-13

Family

ID=3775679

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69231576T Expired - Lifetime DE69231576T2 (de) 1991-09-09 1992-09-09 Verwendung von Peptiden ZUR BEHANDLUNG VON KOMPLIKATIONEN UND PATHOLOGY BEI DIABETES

Country Status (6)

Country Link
US (1) US5561110A (de)
EP (1) EP0666753B9 (de)
JP (1) JPH07500580A (de)
CA (1) CA2117199C (de)
DE (1) DE69231576T2 (de)
WO (1) WO1993004690A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2701948B1 (fr) * 1993-02-22 1996-07-26 Exsymol Sa Produit de couplage de l'histamine ou l'histamine méthyl-substituée et d'un acide aminé, procédé de préparation et applications thérapeutiques, cosmétologiques et agroalimentaires.
IT1270905B (it) * 1993-10-15 1997-05-13 Bruschettini Srl Composizioni farmaceutiche contenenti n-acetilcarnosina per il trattamento della cataratta
WO1995020979A1 (en) * 1994-02-03 1995-08-10 The Picower Institute For Medical Research Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US6410598B1 (en) 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US5750336A (en) * 1994-02-10 1998-05-12 The Salk Institute For Biological Studies Assays for the identification of compounds which inhibit activation of cAMP and mitogen responsive genes
US5576287A (en) * 1994-04-29 1996-11-19 Wake Forest University Method for treating acute renal disease and failure
GB9606076D0 (en) * 1996-03-22 1996-05-22 Univ Birmingham Diabetes treatment
JP3877807B2 (ja) * 1996-07-03 2007-02-07 ゼリア新薬工業株式会社 口内炎治療・予防剤
US5965596A (en) 1997-08-12 1999-10-12 Harris; Roger Methods and compositions for increasing the anaerobic working capacity in tissue
US7504376B2 (en) * 1996-08-12 2009-03-17 Natural Alternatives International Methods and compositions for increasing the anaerobic working capacity in tissues
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US6004958A (en) * 1997-02-05 1999-12-21 Fox Chase Cancer Center Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention
KR100478181B1 (ko) 1998-08-24 2005-03-23 토카이 유니버시티 에듀케이셔널시스템 카르보닐 스트레스상태 개선제 및 복막투석액
CN1331599A (zh) * 1998-10-28 2002-01-16 福克斯契思癌症中心 化合物及其用于治疗糖尿病并发症的用途
US20050170382A1 (en) * 1999-10-06 2005-08-04 The Trustees Of Columbia University In The City Of New York. RAGE-related compositions
RU2165749C1 (ru) * 2000-07-06 2001-04-27 Общество с ограниченной ответственностью "Научно-экспериментальное производство Микрохирургия глаза" Способ восстановления эндотелия роговицы
GB0017028D0 (en) * 2000-07-11 2000-08-30 Ks Biomedix Ltd Peptides and their therapeutic use
US6555573B2 (en) 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
US20030065030A1 (en) * 2001-03-16 2003-04-03 Nobuo Tsuruoka Autonomic controlling agents and health drinks and foods
EP1430018B1 (de) 2001-09-06 2010-12-29 Lonza AG Verfahren zur herstellung von beta-alaninamiden
WO2003032969A2 (en) * 2001-10-15 2003-04-24 National Research Council Of Canada Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
US7435725B2 (en) * 2001-11-06 2008-10-14 The Quigly Corporation Oral compositions and methods for prevention, reduction and treatment of radiation injury
US20030105027A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
JP4504810B2 (ja) * 2002-08-07 2010-07-14 岡山県 微生物由来のポリアミノ酸またはその誘導体
US7083813B2 (en) 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
CA2511217A1 (en) * 2002-12-20 2004-07-15 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US20060166879A1 (en) * 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
WO2005027901A1 (en) * 2003-09-25 2005-03-31 Tel Aviv University Future Technology Development L.P. Compositions and methods using same for treating amyloid-associated diseases
WO2005041870A2 (en) 2003-10-24 2005-05-12 Ader Enterprises, Inc. Composition and method for the treatment of eye disease
FR2863620B1 (fr) * 2003-12-16 2007-05-25 Roquette Freres Utilisation d'au moins un cetose de 3 a 5 atomes de carbone comme substitut d'agents reticulants de proteines
DE10360956A1 (de) * 2003-12-23 2005-07-28 Ruprecht-Karls-Universität Heidelberg System und Verfahren zum Nachweis von diabetischer Nephropatie oder einer Prädisposition dafür
WO2005064013A1 (en) * 2003-12-23 2005-07-14 Bart Janssen The use of carnosine metabolism-associated genes to determine genetic predisposition/susceptibility to diabetic nephropathy
EP1738762A4 (de) * 2004-03-26 2009-07-08 Ajinomoto Kk Mittel zur prävention/behandlung von diabetischen komplikationen mit oligopeptid
US20080194493A1 (en) * 2004-06-08 2008-08-14 Giancarlo Aldini Compositions Containing D-Carnosine
ES2261036B1 (es) * 2004-10-05 2007-12-16 Lipotec, S.A. Peptidos sinteticos que disminuyen o eliminan las bolsas formadas bajo el contorno inferior de los ojos y su uso en composiciones cosmeticas o dermofarmaceuticas.
US20060286046A1 (en) * 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
FR2883873B1 (fr) 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
DK3081215T3 (da) 2005-05-23 2020-04-27 Natural Alternatives Int Inc Sammensætninger og fremgangsmåder til langvarig frigørelse af beta-alanin
RU2335495C2 (ru) 2005-06-15 2008-10-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" N-ацильные производные аминокислот, их фармацевтически приемлевые соли, фармацевтическая композиция и применение в качестве гиполипидемических средств
EA200800338A1 (ru) * 2005-07-15 2008-08-29 Чакшу Рисерч Инк. Профилактика и лечение офтальмологических осложнений диабета
ITMI20061522A1 (it) * 2006-08-01 2008-02-02 Difass S A Composizione ad attivita' antiossidante ed antiglicante migliorata
US20090018151A1 (en) * 2007-02-23 2009-01-15 Ezekiel Fink Topical Treatment of Peripheral diabetic complications
WO2009093990A1 (ru) * 2008-01-25 2009-07-30 Mayank Jain Производные бензимидазола и их применение
RU2598554C2 (ru) * 2012-01-03 2016-09-27 Нестек С.А. Композиции и способы для стабильности реакционноспособных аминокислот в пищевом матриксе
JP6306825B2 (ja) * 2012-11-30 2018-04-04 上野製薬株式会社 終末糖化産物生成抑制剤
PL404174A1 (pl) * 2013-05-31 2014-12-08 Warszawski Uniwersytet Medyczny Zastosowanie pochodnych aminowych jako inhibitorów aktywności interleukiny 15

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508728A (en) * 1984-05-24 1985-04-02 Kineshiro Nagai Method of treating inflammatory diseases
JPS61186322A (ja) * 1985-02-13 1986-08-20 Nippon Univ 免疾調節剤
JPS6314728A (ja) * 1986-07-03 1988-01-21 Zeria Shinyaku Kogyo Kk 肝障害の予防、治療剤
EP0313564A1 (de) * 1986-07-09 1989-05-03 FLAMENT, Daniel Vorrichtung zum festlegen von gegenständen im kofferraum eines fahrzeugs
JPH07116160B2 (ja) * 1987-08-10 1995-12-13 浜理薬品工業株式会社 結晶性ｌ−カルノシン亜鉛錯体およびその製造法
JPH0193526A (ja) * 1987-10-05 1989-04-12 Kaneshiro Nagai 白血球減少の回復剤
EP0436611A4 (en) * 1988-09-28 1992-03-11 Peptide Technology Ltd Compound and method for the retardation of collagen cross-linking
JP2777908B2 (ja) * 1989-06-15 1998-07-23 ゼリア新薬工業株式会社 膵炎治療剤

Also Published As

Publication number Publication date
EP0666753A1 (de) 1995-08-16
EP0666753B1 (de) 2000-11-22
EP0666753B9 (de) 2002-06-12
WO1993004690A1 (en) 1993-03-18
CA2117199A1 (en) 1993-03-18
EP0666753A4 (de) 1995-01-26
JPH07500580A (ja) 1995-01-19
DE69231576T2 (de) 2001-06-13
CA2117199C (en) 2004-12-28
US5561110A (en) 1996-10-01

Similar Documents

Publication Publication Date Title
DE69231576D1 (de) Verwendung von Peptiden ZUR BEHANDLUNG VON KOMPLIKATIONEN UND PATHOLOGY BEI DIABETES
ATE438397T1 (de) Pharmazeutische zubereitung enthaltend pioglitazone und glimepiride zur verwendung in der behandlung von diabetes
DE69325451D1 (de) Verwendung von pyruvamid und ausgewählten pyruvyl-aminosäuren
DE69034018D1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE69327516D1 (de) Verwendung von protein mit erhöhter bakterientötender/durchlassigkeits-erhöhten wirkung und lipid-träger enthaltender zusammensetzung
ATE349428T1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69324958D1 (de) Kompression und Dekompression von Bildern
DE69430990D1 (de) Zusammensetzung und methode zur anreicherung von weissen blutzellen aus menschlichem vollblut
DE68928051D1 (de) Behandlung von humanem Kollagen und Verwendung als Auto-Implantat
DE69324689D1 (de) Verwendung von diacylglycerolen zur steigerung des melaningehaltes in melanozyten
ATE229502T1 (de) Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
DE69320117D1 (de) Kompression und Wiederaufbau von radiologischen Bildern
DE69426690D1 (de) Behandlung von atrophischer Haut und Vagina
DE69212620D1 (de) Verwendung von Glycosaminoglycanen zur Behandlung von diabetischer Nephropathie und diabetischer Neuropathie
ATE286510T1 (de) In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper
HU910605D0 (en) Vectors and molecules for expressing zymogenous form of human c protein
DE69232586D1 (de) Giftigkeit von tnf und lps ausschaltende peptide
DE59408227D1 (de) Haarbehandlungsmittel und Verfahren zur Anwendung
DE69123178D1 (de) Verwendung von Uridin zur pharmakologischen Behandlung der peripheren Komplikationen bei Diabetes
GB9425163D0 (en) Improvements in and relating to treatment of meat
ATE225662T1 (de) Verwendung von unverdaulichen oligosacchariden zur vorbeugung und behandlung von mittelohrentzündung bei menschen
DE69331105D1 (de) Verwendung von thioureleyne und thiabendazol in auto immunbedingten und entzündlichen hauterkrankungen
ZA882624B (en) Treatment of allergy and composition thereof
PT898566E (pt) Benzilaminas substituidas e sua utilizacao no tratamento da depressao
ATE301472T1 (de) Wachstumsfaktoren enthaldende therapeutische homöopathische verdünnungen und verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 666753

Country of ref document: EP